The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1459
ISSUE1459
January 5, 2015
Trumenba: A Serogroup B Meningococcal Vaccine
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Trumenba: A Serogroup B Meningococcal Vaccine
January 5, 2015 (Issue: 1459)
The FDA has approved Trumenba (Pfizer), a vaccine
that protects against invasive meningococcal disease
caused by Neisseria meningitidis serogroup B, for use
in adolescents and young adults 10-25 years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.